MEDPNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Medpace Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$619.66+1.19 (+0.19%)
Close on Oct 19, 2026
- Market cap
- $17.69B
- P/E (TTM)
- 36.3
- Dividend yield
- –
Medpace statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Services-Commercial Physical & Biological Research companies for comparison
Valuation
| Measure | Medpace | Industry median |
|---|---|---|
| Market Cap | $17.30B | $74.60M |
| Enterprise Value | $16.79B | $56.72M |
| PE Ratio | 36.34 | 25.83 |
| PS Ratio | 6.22 | 3.25 |
| PB Ratio | 39.86 | 3.13 |
| P/FCF Ratio | 24.47 | 20.60 |
| P/OCF Ratio | 22.98 | 15.81 |
Enterprise value
| Measure | Medpace | Industry median |
|---|---|---|
| EV / Sales | 6.04 | 2.79 |
| EV / EBITDA | 28.78 | 15.81 |
| EV / EBIT | 28.78 | 22.04 |
| EV / FCF | 23.76 | 21.35 |
Income (trailing twelve months)
| Measure | Medpace | Industry median |
|---|---|---|
| Revenue | $2.78B | $24.74M |
| Operating Income | $583.40M | -$55.64K |
| Pretax Income | $598.92M | $45.62K |
| Net Income | $491.50M | -$97.64K |
| EBITDA | $583.40M | -$29.48K |
| EPS (Diluted) | $17.05 | $0.00 |
Margins
| Measure | Medpace | Industry median |
|---|---|---|
| Operating Margin | 21.0% | 0.94% |
| Pretax Margin | 21.5% | 2.64% |
| Profit Margin | 17.7% | 0.51% |
| EBITDA Margin | 21.0% | 3.48% |
| FCF Margin | 25.4% | 5.05% |
Returns
| Measure | Medpace | Industry median |
|---|---|---|
| Return on Equity (ROE) | 162.2% | 0.45% |
| Return on Assets (ROA) | 27.1% | -3.47% |
| Return on Invested Capital (ROIC) | 1674.2% | 2.85% |
| Return on Capital Employed (ROCE) | 93.8% | 2.03% |
Growth
| Measure | Medpace | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 24.7% | 4.26% |
| Net Income Growth (YoY) | 17.5% | -0.74% |
| EPS Growth (YoY) | 26.8% | 9.14% |
| FCF Growth (YoY) | 21.9% | -10.5% |
| Revenue Growth (3Y CAGR) | 20.1% | 2.15% |
| Revenue Growth (5Y CAGR) | 22.3% | 7.37% |
| EPS Growth (3Y CAGR) | 28.0% | 6.08% |
| EPS Growth (5Y CAGR) | 31.8% | 9.81% |
Balance sheet
| Measure | Medpace | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $502.69M | $5.43M |
| Net Cash (Debt) | $502.69M | $17.62K |
| Net Cash Per Share | $18.01 | $0.00 |
| Equity (Book Value) | $433.86M | $10.50M |
| Book Value Per Share | $15.54 | $0.60 |
| Tangible Book Value | -$261.65M | -$78.36K |
| Working Capital | -$385.14M | $2.78M |
Financial position
| Measure | Medpace | Industry median |
|---|---|---|
| Current Ratio | 0.73 | 1.26 |
| Quick Ratio | 0.66 | 0.65 |
Cash flow (trailing twelve months)
| Measure | Medpace | Industry median |
|---|---|---|
| Operating Cash Flow | $752.66M | $8.04K |
| Capital Expenditures | -$45.97M | -$8.33M |
| Free Cash Flow | $706.69M | $11.03M |
| FCF Per Share | $25.32 | $0.76 |
Efficiency
| Measure | Medpace | Industry median |
|---|---|---|
| Asset Turnover | 1.53 | 0.83 |
| Revenue Per Employee | $448.76K | $216.23K |
| Profits Per Employee | $79.27K | -$3.19K |
| Employee Count | 6,200 | 123 |
Dividends and yields
| Measure | Medpace | Industry median |
|---|---|---|
| Earnings Yield | 2.84% | -0.97% |
| FCF Yield | 4.09% | 3.90% |
| Buyback Yield | 1.73% | 1.36% |
| Shareholder Yield | 1.73% | 1.65% |
Shares
| Measure | Medpace | Industry median |
|---|---|---|
| Shares Outstanding | 27,911,700 | 29,217,800 |
| Shares Change (YoY) | -7.23% | 0.84% |
| Shares Change (QoQ) | -2.27% | 0.00% |
| Float | 22,312,400 | 26,226,050 |
| Shares Held by Insiders | 20.1% | 4.85% |
| Shares Held by Institutions | 88.5% | 83.3% |
Taxes
| Measure | Medpace | Industry median |
|---|---|---|
| Income Tax | $107.42M | $1.36M |
| Effective Tax Rate | 17.9% | 23.6% |
Scores
| Measure | Medpace | Industry median |
|---|---|---|
| Graham Number | $77.22 | $16.51 |
| Graham Upside | -87.5% | -50.2% |
| Altman Z-Score | 8.11 | 2.66 |
| Piotroski F-Score | 6 | 5 |
Calculated by StockData from Medpace's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.